Preclinical studies indicate that strategies including targeting KP activity using TRP supplementation, KP enzyme inhibitors, or analogs of KP metabolites appear to be noteworthy therapeutic options against the excitotoxicity and oxidative stress accompanying neurological disorders as well as a neuroprotective solution. The gene discussed is NPPA; the disease is nervous system disorder.